Concepedia
Statistics
Publications
6
Citations
204
H-Index
Active since
2019
Affiliations
Mitsubishi Corporation (United States)(Current)
Montreal Neurological Institute and Hospital
Carolinas Medical Center
Neurosciences Institute
Temple University
Stephen Apple is an author at Mitsubishi Corporation (United States) specializing in drug safety, pharmacotherapy, and clinical trials.
Top concepts
HealthMedicineNeurologyToxicologyDrug SafetyPharmacologyClinical TrialsPharmacotherapyPharmacokineticsClinical Pharmacology
Publications per year
2019–2022
Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19)
Jeremy M. Shefner, Terry Heiman‐Patterson, Erik P. Pioro et al. · Muscle & Nerve · 2019 · 74 citations · Full text
Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19
Ammar Al‐Chalabi, Adriano Chiò, Charlotte Merrill et al. · Journal of Neurology Neurosurgery & Psychiatry · 2020 · 37 citations · Full text
Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]
Benjamin Rix Brooks, Terry Heiman‐Patterson, Martina Wiedau‐Pazos et al. · PLoS ONE · 2022 · 28 citations · Full text
Pharmacokinetics, Bioavailability, and Swallowing Safety With Riluzole Oral Film
James Wymer, Stephen Apple, Antoinette Harrison et al. · Clinical Pharmacology in Drug Development · 2022 · 24 citations · Full text
Drug Safety, Pharmaceutical Science, Amyotrophic Lateral Sclerosis +13
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment
Angela Genge, Gary L. Pattee, Gen Sobue et al. · Muscle & Nerve · 2022 · 24 citations · Full text
1–5 of 6